Τίτλος:
Economic evaluation of pharmacogenomic-guided warfarin treatment for
elderly Croatian atrial fibrillation patients with ischemic stroke
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background & methods: Economic evaluation in genomic medicine is an
emerging discipline to assess the cost-effectiveness of genome-guided
treatment. Here, we developed a pharmaco-economic model to assess
whether pharmacogenomic (PGx)-guided warfarin treatment of elderly
ischemic stroke patients with atrial fibrillation in Croatia is cost
effective compared with non-PGx therapy. The time horizon of the model
was set at 1 year. Results: Our primary analysis indicates that 97.07%
(95% CI: 94.08-99.34%) of patients belonging to the PGx-guided group
have not had any major complications, compared with the control group
(89.12%; 95% CI: 84.00-93.87%, p < 0.05). The total cost per patient
was estimated at Euro538.7 (95% CI: Euro526.3-551.2) for the PGx-guided
group versus Euro219.7 (95% CI: Euro137.9-304.2) for the control group.
In terms of quality-adjusted life-years (QALYs) gained, total QALYs was
estimated at 0.954 (95% CI: 0.943-0.964) and 0.944 (95% CI:
0.931-0.956) for the PGx-guided and the control groups, respectively.
The true difference in QALYs was estimated at 0.01 (95% CI:
0.005-0.015) in favor of the PGx-guided group. The incremental
cost-effectiveness ratio of the PGx-guided versus the control groups was
estimated at Euro31,225/QALY. Conclusion: Overall, our data indicate
that PGx-guided warfarin treatment may represent a cost-effective
therapy option for the management of elderly patients with atrial
fibrillation who developed ischemic stroke in Croatia. Original
submitted 4 June 2014; Revision submitted 12 November 2014
Συγγραφείς:
Mitropoulou, Christina
Fragoulakis, Vasilios
Bozina, Nada and
Vozikis, Athanassios
Supe, Svjetlana
Bozina, Tamara and
Poljakovic, Zdravka
van Schaik, Ron H.
Patrinos, George P.
Περιοδικό:
Current Pharmacogenomics
Εκδότης:
Future Medicine Ltd
Λέξεις-κλειδιά:
atrial fibrillation; cost-effectiveness analysis; ischemic stroke;
pharmacogenomics economic evaluation; warfarin
